A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

NCT05573230 · Completed

Last updated 2026-05-28

This study tests how the drug LY3502970 interacts with cyclosporine in healthy adults by measuring how the body processes LY3502970.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 32 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2022-10 · est. completion 2023-01

Where 1 site · Singapore

What this study is testing ClinicalTrials.gov NCT05573230 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants. The study will also evaluate the safety and tolerability of LY3502970 in healthy participants. This study will last up to approximately 76 days for each participant.

Treatments tested

Midazolam Drug

Administered orally.
LY3502970 Drug

Administered orally.
Cyclosporine Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05573230 ↗